Author:
Trinh Kelly,Chow David Z.,Park Hyesun,Habib Ukasha,Offit Lily,Franquet Elisa,Almeida Renata R.,Wang Yingbing,Borges Nuno,Jamal Faisal,Jacene Heather A.,Heidari Pedram,Ng Thomas S.C.
Reference49 articles.
1. PSMA PET-CT in the diagnosis and staging of prostate cancer;Combes;Diagnostics,2022
2. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions;Paller;Clin Adv Hematol Oncol HO,2013
3. Incorporating PSMA-targeting theranostics into personalized prostate cancer treatment: a multidisciplinary perspective;Ng;Front Oncol. Switzerland,2021
4. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial;Calais;Lancet Oncol,2019
5. PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy;Jones;Cancers,2020